The role of IGF1 in determining body composition in children and adolescents with growth hormone deficiency and those with idiopathic short stature.
bioelectrical impedance analysis (BIA)
fat percentage
muscle mass
muscle-to-fat ratio
pediatric patients
sex dimorphism
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
14 Aug 2024
14 Aug 2024
Historique:
received:
30
04
2024
accepted:
02
08
2024
medline:
15
8
2024
pubmed:
15
8
2024
entrez:
14
8
2024
Statut:
aheadofprint
Résumé
Treatment with recombinant human growth hormone (rhGH) increases insulin growth factor-1 (IGF1) levels, therefore, monitoring both IGF1 and growth constitutes an acceptable parameter of therapeutic safety and efficacy. We aimed to investigate the relationship between IGF1 level and body composition in children and adolescents undergoing rhGH therapy for growth hormone deficiency (GHD) and idiopathic short stature (ISS). This observational retrospective study included the bioimpedance analysis (BIA) reports (n = 305) of 135 pediatric patients (age 5-18 years), 64 with GHD and 71 with ISS, conducted as part of routine clinic visits. Sociodemographic and clinical data were extracted from medical records. Generalized estimating equations linear models were used to explore the contributing factors for body composition components of fat percentage (FATP), appendicular skeletal muscle mass (ASMM) z-score, and muscle-to-fat ratio (MFR) z-score while adjusting for cumulative doses of rhGH. Subjects with GHD exhibited higher body mass index z-scores (p < 0.001), higher FATP and truncal FATP scores, lower MFR z-score, and higher diastolic blood pressure percentiles than the ISS group (p = 0.010, p = 0.027, p = 0.050, and p = 0.050, respectively). Female sex (p < 0.001) and a GHD diagnosis (p < 0.001), were major contributors to higher FATP scores; female sex (p = 0.049) and ISS diagnosis (p = 0.005) were major contributors to higher MFR z-scores; and female sex (p < 0.001), older age (p < 0.001) and higher insulin-like growth factor 1 z-scores (p = 0.021) were major contributors to higher ASMM z-scores. Socioeconomic position and cumulative rhGH dose were not significant contributors to body composition parameters. Children with GHD, including those undergoing rhGH treatment, may be at risk for increased adiposity and associated metabolic implications. Sex- and age-adjusted IGF1 levels were related to muscle mass but not to adiposity. Hence, rhGH treatment aimed at increasing IGF1 levels may alleviate these effects by promoting muscle growth.
Identifiants
pubmed: 39143422
doi: 10.1007/s12020-024-03992-0
pii: 10.1007/s12020-024-03992-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
A. Grimberg, D.B. Allen, Growth hormone treatment for growth hormone deficiency and idiopathic short stature: new guidelines shaped by the presence and absence of evidence. Curr. Opin. Pediatr. 29, 466–471 (2017). https://doi.org/10.1097/MOP.0000000000000505
doi: 10.1097/MOP.0000000000000505
pubmed: 28525404
pmcid: 5565215
P. Wang, B. Ji, Q. Shao, M. Zhang, B. Ban: Association between insulin-like growth factor-1 and uric acid in Chinese children and adolescents with idiopathic short stature: a cross-sectional study. Biomed Res. Int. 2018, (2018). https://doi.org/10.1155/2018/4259098
C. Duan, H. Ren, S. Gao, Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins: Roles in skeletal muscle growth and differentiation. Gen. Comp. Endocrinol. 167, 344–351 (2010). https://doi.org/10.1016/J.YGCEN.2010.04.009
doi: 10.1016/J.YGCEN.2010.04.009
pubmed: 20403355
A. Brener et al. Insulin-like growth factor-1 status is associated with insulin resistance in young patients with spinal muscular atrophy. Neuromuscul. Disord. 30, 888–896 (2020). https://doi.org/10.1016/j.nmd.2020.09.025
doi: 10.1016/j.nmd.2020.09.025
pubmed: 33071067
C.P. Hawkes, A. Grimberg, Insulin-like growth Factor-I is a marker for the nutritional state. Pediatr. Endocrinol. Rev. 13, 499 (2015)
pubmed: 26841638
pmcid: 5576178
T.V. Bersin et al. Nutritional status affects Igf1 regulation of skeletal muscle myogenesis, myostatin, and myofibrillar protein degradation pathways in gopher rockfish (Sebastes carnatus). Mol. Cell. Endocrinol. 573, 111951 (2023). https://doi.org/10.1016/J.MCE.2023.111951
doi: 10.1016/J.MCE.2023.111951
pubmed: 37169322
A. Pawlikowska-Haddal, P. Cohen, D.M. Cook, How useful are serum IGF-I measurements for managing GH replacement therapy in adults and children? Pituitary 15, 126–134 (2012). https://doi.org/10.1007/S11102-011-0343-Y/TABLES/5
doi: 10.1007/S11102-011-0343-Y/TABLES/5
pubmed: 21909971
A. Grimberg et al. Guidelines for growth hormone and insulin-like growth Factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth Factor-I deficiency. Horm. Res. Paediatr. 86, 361–397 (2017). https://doi.org/10.1159/000452150
doi: 10.1159/000452150
A. Brener et al. Beyond Body Mass Index - Body composition assessment by bioimpedance in routine endocrine practice. Endocr. Pract. 27, 419–425 (2021). https://doi.org/10.1016/j.eprac.2020.10.013
doi: 10.1016/j.eprac.2020.10.013
pubmed: 33934752
S.D. De Ferranti et al. Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation 110, 2494–2497 (2004). https://doi.org/10.1161/01.CIR.0000145117.40114.C7
doi: 10.1161/01.CIR.0000145117.40114.C7
pubmed: 15477412
G.E. Duncan, S.M. Li, X.H. Zhou, Prevalence and trends of a metabolic syndrome phenotype among U.S. adolescents, 1999-2000. Diabetes Care 27, 2438–2443 (2004). https://doi.org/10.2337/DIACARE.27.10.2438
doi: 10.2337/DIACARE.27.10.2438
pubmed: 15451913
J. Steinberger et al. Progress and challenges in metabolic syndrome in children and adolescents. Circulation 119, 628–647 (2009). https://doi.org/10.1161/CIRCULATIONAHA.108.191394
doi: 10.1161/CIRCULATIONAHA.108.191394
pubmed: 19139390
A. Brener et al. The endocrine manifestations of spinal muscular atrophy, a real-life observational study. Neuromuscul. Disord. 30, 270–276 (2020). https://doi.org/10.1016/j.nmd.2020.02.011
doi: 10.1016/j.nmd.2020.02.011
pubmed: 32273202
N. Salton et al. Muscle-to-fat ratio for predicting metabolic syndrome components in children with overweight and obesity. Child. Obes. 18, 132–142 (2022). https://doi.org/10.1089/CHI.2021.0157
doi: 10.1089/CHI.2021.0157
pubmed: 34550798
A. Yerushalmy-Feler et al. Body composition in pediatric celiac disease and metabolic syndrome component risk-an observational study. Pediatr. Res. 94, 618–625 (2023). https://doi.org/10.1038/S41390-023-02496-3
doi: 10.1038/S41390-023-02496-3
pubmed: 36707663
A. Ben Simon et al. Body composition in children and adolescents with non-classic congenital adrenal hyperplasia and the risk for components of metabolic syndrome: An observational study. Front. Endocrinol. 13, 1022752 (2022). https://doi.org/10.3389/FENDO.2022.1022752/BIBTEX
doi: 10.3389/FENDO.2022.1022752/BIBTEX
Israel Central Bureau of Statistics. Characterization and Classification of Geographical Units by the Socio-Economic Level of the Population, 2015. (2020). https://www.cbs.gov.il/he/publications/DocLib/2020/1765_socio_economic_2015/e_print.pdf .
A. Grimberg, C.P. Hawkes, Growth Hormone Treatment for Non-GHD Disorders: Excitement Tempered by Biology. J. Clin. Endocrinol. Metab. 109, e442–e454 (2024). https://doi.org/10.1210/clinem/dgad417
doi: 10.1210/clinem/dgad417
pubmed: 37450564
M. Yackobovitch-Gavan, L. Lazar, R. Diamant, M. Phillip, T. Oron, Diagnosis of growth hormone deficiency in children: the efficacy of glucagon versus clonidine stimulation test. Horm. Res. Paediatr. 93, 470–476 (2021). https://doi.org/10.1159/000513393
doi: 10.1159/000513393
M. Bidlingmaier et al. Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J. Clin. Endocrinol. Metab. 99, 1712–1721 (2014). https://doi.org/10.1210/JC.2013-3059
doi: 10.1210/JC.2013-3059
pubmed: 24606072
P. Chanson et al. Reference values for IGF-I Serum concentrations: comparison of six immunoassays. J. Clin. Endocrinol. Metab. 101, 3450–3458 (2016). https://doi.org/10.1210/JC.2016-1257
doi: 10.1210/JC.2016-1257
pubmed: 27167056
pmcid: 5054194
R.J. Kuczmarski et al.: CDC growth charts: United States. Adv. Data 1-27 (2000). https://stacks.cdc.gov/view/cdc/11267
J.M. Tanner, H. Goldstein, R.H. Whitehouse, Standards for children’s height at ages 2-9 years allowing for height of parents. Arch. Dis. Child. 45, 755–762 (1970). https://doi.org/10.1136/ADC.45.244.755
doi: 10.1136/ADC.45.244.755
pubmed: 5491878
pmcid: 1647404
S.E. Barlow, W.H. Dietz, Obesity evaluation and treatment: Expert Committee recommendations. The Maternal and Child Health Bureau, Health Resources and Services Administration and the Department of Health and Human Services. Pediatrics 102, e29 (1998). https://doi.org/10.1542/PEDS.102.3.E29
doi: 10.1542/PEDS.102.3.E29
pubmed: 9724677
T.J. Cole, K.M. Flegal, D. Nicholls, A.A. Jackson, Body mass index cut offs to define thinness in children and adolescents: international survey. BMJ 335, 194–197 (2007). https://doi.org/10.1136/BMJ.39238.399444.55
doi: 10.1136/BMJ.39238.399444.55
pubmed: 17591624
pmcid: 1934447
J.H. Chou, S. Roumiantsev, R. Singh: PediTools electronic growth chart calculators: applications in clinical care, research, and quality improvement. J. Med. Internet Res. 22, (2020). https://doi.org/10.2196/16204
Shypailo R.J.: Age-Based Pediatric Blood Pressure Reference Charts. from the Baylor College of Medicine, Children’s Nutrition Research Q21 Center, Body Composition Laboratory. (2018). http://www.bcm.edu/bodycomplab/BPappZjs/BPvAgeAPPz.html
W.A. Marshall, J.M. Tanner, Variations in the pattern of pubertal changes in boys. Arch. Dis. Child. 45, 13–23 (1970). https://doi.org/10.1136/ADC.45.239.13
doi: 10.1136/ADC.45.239.13
pubmed: 5440182
pmcid: 2020414
W.A. Marshall, J.M. Tanner, Variations in pattern of pubertal changes in girls. Arch. Dis. Child. 44, 291–303 (1969). https://doi.org/10.1136/ADC.44.235.291
doi: 10.1136/ADC.44.235.291
pubmed: 5785179
pmcid: 2020314
C.E. Orsso, M.C. Gonzalez, M.J. Maisch, A.M. Haqq, C.M. Prado, Using bioelectrical impedance analysis in children and adolescents: Pressing issues. Eur. J. Clin. Nutr. 76, 659–665 (2022). https://doi.org/10.1038/S41430-021-01018-W
doi: 10.1038/S41430-021-01018-W
pubmed: 34620999
H.D. McCarthy, D. Samani-Radia, S.A. Jebb, A.M. Prentice, Skeletal muscle mass reference curves for children and adolescents. Pediatr. Obes. 9, 249–259 (2014). https://doi.org/10.1111/J.2047-6310.2013.00168.X
doi: 10.1111/J.2047-6310.2013.00168.X
pubmed: 23776133
L. Lello et al. Accurate genomic prediction of human height. Genetics 210, 477–497 (2018). https://doi.org/10.1534/GENETICS.118.301267
doi: 10.1534/GENETICS.118.301267
pubmed: 30150289
pmcid: 6216598
M.O. Savage, H.L. Storr, G.H. Resistance, Is a component of idiopathic short stature: implications for rhGH therapy. Front Endocrinol. 12, 781044 (2021). https://doi.org/10.3389/FENDO.2021.781044/BIBTEX
doi: 10.3389/FENDO.2021.781044/BIBTEX
A. Brener et al. The heritability of body composition. BMC Pediatr. 21, 1–8 (2021). https://doi.org/10.1186/S12887-021-02695-Z/FIGURES/1
doi: 10.1186/S12887-021-02695-Z/FIGURES/1
G.A. Bray, R.M. Krauss, F.M. Sacks, L. Qi, Lessons learned from the POUNDS lost study: genetic, metabolic, and behavioral factors affecting changes in body weight, body composition, and cardiometabolic risk. Curr. Obes. Rep. 8, 262–283 (2019). https://doi.org/10.1007/S13679-019-00353-1/TABLES/3
doi: 10.1007/S13679-019-00353-1/TABLES/3
pubmed: 31214942
S.A. Beshyah et al. Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults. Clin. Endocrinol. 42, 179–189 (1995). https://doi.org/10.1111/J.1365-2265.1995.TB01860.X
doi: 10.1111/J.1365-2265.1995.TB01860.X
G. Johannsson et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J. Clin. Endocrinol. Metab. 82, 727–734 (1997). https://doi.org/10.1210/JCEM.82.3.3809
doi: 10.1210/JCEM.82.3.3809
pubmed: 9062473
D. Maiter et al. Baseline characteristics and response to GH replacement of hypopituitary patients previously irradiated for pituitary adenoma or craniopharyngioma: data from the Pfizer International Metabolic Database. Eur. J. Endocrinol. 155, 253–260 (2006). https://doi.org/10.1530/EJE.1.02209
doi: 10.1530/EJE.1.02209
pubmed: 16868138
F. Salomon, R.C. Cuneo, R. Hesp, P.H. Sönksen, The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N. Engl. J. Med. 21, 1797–1803 (2010). https://doi.org/10.1056/NEJM198912283212605
doi: 10.1056/NEJM198912283212605
A.F. Attanasio et al. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status—3-year results from the HypoCCS database. J. Clin. Endocrinol. Metab. 87, 1600–1606 (2002). https://doi.org/10.1210/JCEM.87.4.8429
doi: 10.1210/JCEM.87.4.8429
pubmed: 11932289
N. Moøller, J.O.L. Joørgensen, Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr. Rev. 30, 152–177 (2009). https://doi.org/10.1210/ER.2008-0027
doi: 10.1210/ER.2008-0027
A. Chrisoulidou et al. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. J. Clin. Endocrinol. Metab. 85, 3762–3769 (2000). https://doi.org/10.1210/JCEM.85.10.6910
doi: 10.1210/JCEM.85.10.6910
pubmed: 11061536
C. Franco et al. The reduction in visceral fat mass in response to growth hormone is more marked in men than in oestrogen-deficient women. Growth Horm. IGF Res. 19, 112–120 (2009). https://doi.org/10.1016/J.GHIR.2008.07.001
doi: 10.1016/J.GHIR.2008.07.001
pubmed: 18752977
A.R. Hoffman et al. Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 89, 2048–2056 (2004). https://doi.org/10.1210/JC.2003-030346
doi: 10.1210/JC.2003-030346
pubmed: 15126520
Y.J. Lee et al. Metabolic impacts of discontinuation and resumption of recombinant human growth hormone treatment during the transition period in patients with childhood-onset growth hormone deficiency. Endocrinol. Metab. 37, 359–368 (2022). https://doi.org/10.3803/ENM.2021.1384
doi: 10.3803/ENM.2021.1384
I.M. Van Der Sluis et al. Long-term effects of growth hormone therapy on bone mineral density, body composition, and serum lipid levels in growth hormone deficient children: a 6-year follow-up study. Horm. Res. 58, 207–214 (2002). https://doi.org/10.1159/000066262
doi: 10.1159/000066262
pubmed: 12401939
J.N. Roemmich, M.G. Huerta, S.M. Sundaresan, A.D. Rogol, Alterations in body composition and fat distribution in growth hormone—Deficient prepubertal children during growth hormone therapy. Metabolism 50, 537–547 (2001). https://doi.org/10.1053/META.2001.22510
doi: 10.1053/META.2001.22510
pubmed: 11319714
A. Brener et al.: Sex differences in body composition in youth with type 1 diabetes and its predictive value in cardiovascular disease risk assessment. Diabetes. Metab. Res. Rev. 39, (2023). https://doi.org/10.1002/DMRR.3584
G. Rodríguez et al.: Skinfold measurements at birth: sex and anthropometric influence. Arch. Dis. Child. Fetal Neonatal. Ed. 90, (2005). https://doi.org/10.1136/ADC.2004.060723
L.M. Maynard et al. Childhood body composition in relation to body mass index. Pediatrics 107, 344–350 (2001). https://doi.org/10.1542/PEDS.107.2.344
doi: 10.1542/PEDS.107.2.344
pubmed: 11158468
Y.F. Pei et al. The genetic architecture of appendicular lean mass characterized by association analysis in the UK Biobank study. Commun. Biol. 3, 1–13 (2020). https://doi.org/10.1038/s42003-020-01334-0
doi: 10.1038/s42003-020-01334-0
J.P. Chaput et al. 2020 WHO guidelines on physical activity and sedentary behaviour for children and adolescents aged 5–17 years: summary of the evidence. Int. J. Behav. Nutr. Phys. Act. 17, 1–9 (2020). https://doi.org/10.1186/S12966-020-01037-Z/TABLES/6
doi: 10.1186/S12966-020-01037-Z/TABLES/6
A.G. Johansson, Gender difference in growth hormone response in adults. J. Endocrinol. Invest 22, 58–60 (1999)
pubmed: 10442572
R. Coutant et al. Divergent effect of endogenous and exogenous sex steroids on the insulin-like growth factor I response to growth hormone in short normal adolescents. J. Clin. Endocrinol. Metab. 89, 6185–6192 (2004). https://doi.org/10.1210/JC.2004-0814
doi: 10.1210/JC.2004-0814
pubmed: 15579776
S.S. Ahmad, K. Ahmad, E.J. Lee, Y.H. Lee, I. Choi: Implications of insulin-like growth Factor-1 in skeletal muscle and various diseases. Cells 9, (2020). https://doi.org/10.3390/CELLS9081773
M.L. Adamo, R.P. Farrar, Resistance training, and IGF involvement in the maintenance of muscle mass during the aging process. Ageing Res. Rev. 5, 310–331 (2006). https://doi.org/10.1016/J.ARR.2006.05.001
doi: 10.1016/J.ARR.2006.05.001
pubmed: 16949353
G. Vitale, G. Pellegrino, M. Vollery, L.J. Hofland, ROLE of IGF-1 system in the modulation of longevity: controversies and new insights from a centenarians’ perspective. Front. Endocrinol. 10, 27 (2019). https://doi.org/10.3389/FENDO.2019.00027
doi: 10.3389/FENDO.2019.00027